×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.

Contributors

Isabelle Desmoulins, Dijon, France
Rachel Groubet, Strasbourg, France
Jean-Emmanuel Kurtz, Strasbourg, France
Sylvain Ladoire, Dijon, France
Thierry Petit, Strasbourg, France
Thursday, October 13th 2022 from 06pm to 07pm (GMT+2)
Honolulu : Thursday, October 13th 2022 from 07am to 08am (GMT+2)
San Francisco : Thursday, October 13th 2022 from 10am to 11am (GMT+2)
New York : Thursday, October 13th 2022 from 01pm to 02pm (GMT+2)
Buenos Aires : Thursday, October 13th 2022 from 02pm to 03pm (GMT+2)
Reykjavik : Thursday, October 13th 2022 from 05pm to 06pm (GMT+2)
London / Dublin : Thursday, October 13th 2022 from 06pm to 07pm (GMT+2)
Paris / Berlin : Thursday, October 13th 2022 from 07pm to 08pm (GMT+2)
Istanbul : Thursday, October 13th 2022 from 08pm to 09pm (GMT+2)
Moscou / Dubaï : Thursday, October 13th 2022 from 09pm to 10pm (GMT+2)
Bangkok : Friday, October 14th 2022 from 12am to 01am (GMT+2)
Shanghai : Friday, October 14th 2022 from 01am to 02am (GMT+2)
Tokyo : Friday, October 14th 2022 from 02am to 03am (GMT+2)
Sydney : Friday, October 14th 2022 from 04am to 05am (GMT+2)
Wellington : Friday, October 14th 2022 from 06am to 07am (GMT+2)

Les inhibiteurs de tyrosine kinase (TKI) et les anticorps conjugués (ADC) dans le cancer du sein mÃ...

Les nouveaux traitements, entre choix et complémentarité

Share
Scroll Up